- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo ; volume:84 ; number:5 ; day:16 ; month:4 ; year:2024 ; pages:579-586 ; date:5.2024
Drugs ; 84, Heft 5 (16.4.2024), 579-586, 5.2024
- Creator
-
Kang, Connie
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-024-02027-2
- URN
-
urn:nbn:de:101:1-2409122102552.542696717009
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kang, Connie
- SpringerLink (Online service)
Other Objects (12)
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Circadian clock gene expression and polymorphism in non-segmental vitiligo
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
Metabolomic signature of amino acids in plasma of patients with non-segmental Vitiligo
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Circadian clock gene expression and polymorphism in non-segmental vitiligo
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
Metabolomic signature of amino acids in plasma of patients with non-segmental Vitiligo
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Circadian clock gene expression and polymorphism in non-segmental vitiligo
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis